Do angiotensin converting enzyme inhibitors prevent the left ventricular diastolic dysfunction in patients with metabolic syndrome?

2009 ◽  
Vol 18 ◽  
pp. S241
Author(s):  
D. Radulescu ◽  
S. Pripon ◽  
Elena Buzdugan ◽  
Andreea Parv ◽  
Maria Radulescu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Converting Enzyme ◽  
Diastolic Dysfunction ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Left Ventricular Diastolic Dysfunction ◽  
Left Ventricular ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Ventricular Diastolic Dysfunction

Angiotensin-Converting Enzyme Inhibition after Myocardial Infarction

2000 ◽  
Vol 8 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Yi Zhun Zhu ◽  
How Sung Lee
Keyword(s):  
Myocardial Infarction ◽  
Clinical Trials ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Experimental Studies ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Left Ventricular ◽  
Angiotensin Converting Enzyme Inhibition ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

Myocardial infarction was the underlying event in the majority of deaths from cardiovascular disease in Western countries in the past quarter-century. The introduction of angiotensin-converting enzyme inhibitors to the treatment of heart failure following myocardial infarction was a major advance in the last 10 years. However, the role of cardiac angiotensin-converting enzyme during postinfarction cardiac remodeling remains to be elucidated. Experimental studies demonstrated that angiotensin-converting enzyme inhibitors administered one week before myocardial infarction could limit infarct size, improve cardiac function, and prevent cardiac hypertrophy. Numerous large-scale clinical trials have shown that angiotensin-converting enzyme inhibitors are safe and can reduce mortality and the occurrence of severe left ventricular dysfunction after myocardial infarction. This review focuses on the effects of these inhibitors in experimental studies and in multicenter clinical trials.

scholarly journals Medicines in the rehabilitation of patients after myocardial infarction: angiotensin-converting enzyme inhibitors

2010 ◽  
Vol 1 (1) ◽  
pp. 62-64
Author(s):  
A. S Galyavich
Keyword(s):  
Myocardial Infarction ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitors ◽  
Ventricular Dysfunction ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Left Ventricular ◽  
Diabetic Patients ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

The paper analyzes the use of angiotensin-converting enzyme (ACE) inhibitors in patients after prior myocardial infarction. It presents the data of controlled studies, which indicate that it is warranted to use ACE inhibitors to improve prognosis in patients. It is concluded that it is unreasonable for a physician not to prescribe ACE inhibitors to post-myocardial infarction patients with obvious or asymptomatic left ventricular dysfunction and to diabetic patients (if no contraindications).

Sign in / Sign up

Export Citation Format

Share Document